What are the common side effects of Tucatinib and can they be alleviated?

In recent years, with the continuous deepening of HER2 targeted treatment strategies, tucatinib (Tucatinib, Chinese name tucatinib) has gradually entered the mainstream treatment of advanced HER2 positive breast cancer. As a highly selective HER2 tyrosine kinase inhibitor (TKI), tucatinib has excellent performance in prolonging survival and delaying disease progression, especially in patients with brain metastases. However, like other targeted drugs, tucatinib may also come with a range of side effects. This article will focus on the common side effects, causes, relief methods, and management suggestions in clinical use of tucatinib to provide patients with a comprehensive reference.

1. The mechanism of action and target characteristics of tucatinib

Tucatinib is an oral HER2 selective tyrosine kinase inhibitor that can bind to the intracellular tyrosine kinase domain of the HER2 receptor, inhibit its signaling, and thereby block the proliferation and survival of HER2 positive tumor cells. Due to its high selectivity, it has less impact on HER1 (EGFR). Therefore, compared with the first-generation HER inhibitors such as lapatinib, its side effect spectrum is more "mild", especially in terms of rash, diarrhea, etc., which are more controllable.

2. Common side effects of tucatinib

Based on clinical trials (such as the HER2CLIMB study) and real-world drug data, common side effects of tucatinib mainly include the following categories:

1. Gastrointestinal discomfort

Diarrhea: The most common side effect, with a high incidence, accounting for more than 60% of patients, but most of them are 1-2 mild to moderate, and 3 severe diarrhea is less common.

Nausea and vomiting: About30%-40% of patients may experience it, and the degree is usually mild.

Decreased appetite and indigestion: This may occur in a small number of patients, affecting eating and weight maintenance.

2. Abnormal liver function

Tucatinib can cause transient elevation of transaminases (such asALT,AST), especially in combination with capecitabine or trastuzumab.

Elevated bilirubin may occur in some patients, but severe liver injury is rare.

3. Fatigue and weakness

Nearly30%-40% of patients will report varying degrees of fatigue during treatment, which affects daily activities, but it can usually be relieved or recover on its own.

4. Hand-foot syndrome

Tucatinib itself has a low risk of causing hand-foot syndrome, but when used in combination with capecitabine, the incidence of hand-foot syndrome (such as redness, swelling, pain, and peeling of the skin of the hands and feet) increases.

5. Central nervous system symptoms (related to brain metastasis)

Tucatinib has a strong ability to pass through the blood-brain barrier and is effective in the treatment of brain metastases. However, a very few patients may experience mild neurological discomfort such as headache, dizziness, and confusion, which needs to be distinguished from tumor progression.

3. Side effects mitigation methods and management suggestions

1. Diarrhea Management

It is recommended that patients prepare regular antidiarrheal drugs, such as loperamide (Imodium) before taking the medicine;

When symptoms of diarrhea occur, promptly adjust the dosage or increase fluid rehydration as directed by the doctor to avoid electrolyte imbalance;

It is recommended to adopt a low-fat, low-fiber diet and avoid greasy food.

2. Nausea and poor appetite

You can take antiemetic drugs such as Austatin, along with small, frequent meals and easy-to-digest foods;

If necessary, you can appropriately supplement vitaminsB6 or ginger preparations to relieve discomfort.

3. Liver function monitoring and protection

It is recommended to monitor liver function every 1-2 weeks in the early stage of treatment, especially ALT, AST and bilirubin;

If it is found that the increase exceeds the normal value2-3 times or more, the medication should be suspended or the dose should be reduced, and liver-protective drugs should be used as appropriate;

Be careful to avoid taking drugs that affect the liver (such as acetaminophen, alcohol, etc.) at the same time.

4. Fatigue and decreased physical strength

Moderate exercise (such as walking, Tai Chi) can improve fatigue;

Ensure sleep quality and avoid overexertion;

If symptoms are severe, the patient may be evaluated for complications such as anemia and electrolyte imbalance.

5. Skin reactions or hand-foot syndrome caused by combined medication

When your hands and feet become red or peeling, you can use urea cream, vitaminE cream and other moisturizing and repairing products;

Avoid prolonged friction, high temperature or contact with harsh detergents on your hands and feet;

Adjust the capecitabine dose if necessary to reduce combined side effects.

4. Dose adjustment and safety monitoring in clinical use

The recommended dose of tucatinib is 300 mg orally twice daily, which can be taken with food. If intolerable adverse reactions occur, the dose can be adjusted according to medical advice. A common adjustment plan is to reduce to 250mg or 150mg. Dose adjustment does not necessarily affect the efficacy; the key is to maintain the sustainability of long-term treatment and the patient's quality of life.

At the same time, it is recommended that patients review basic indicators such as liver function, electrolyte levels, and blood routine every month. If trastuzumab and capecitabine are used in combination, attention must also be paid to issues such as cardiac function, hand-foot reaction, and hemogram suppression.

5. Summary and patient suggestions

In general, as a new generation of highly selective HER2 targeted drug, tucatinib has a relatively mild side effect spectrum, and most of the side effects are predictable and manageable. Common discomforts such as diarrhea, fatigue, elevated liver enzymes, etc. can usually be effectively relieved through drug regulation, dietary adjustment and dosage intervention under the guidance of a doctor.

For patients who are receiving tucatinib treatment, it is recommended to conduct a basic health assessment before treatment, establish a good communication mechanism with the attending doctor, promptly report side effects and cooperate with treatment adjustments. While paying attention to the effects of treatment, we should also pay attention to the management of side effects to ensure the continuity of treatment and quality of life.

In the future, with the accumulation of more real-world data and the development of combination studies with other new immune and antibody drugs, tucatinib will be more widely used in the treatment of HER2-positive tumors, and side effect management will become increasingly standardized and individualized.

Reference materials:https://www.drugs.com/